Loading
Life sciences · Journal article
Discover Oncology · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
MicroRNA-377 (miR-377) is a predominantly tumor-suppressive microRNA with context-dependent functions in cancer. Located within the imprinted DLK1-DIO3 region on chromosome 14q32, miR-377 regulates proliferation, apoptosis, invasion, metastasis, and treatment response, and its dysregulation contributes to cancer development, progression, and therapy resistance. This review examines the molecular basis of miR-377 silencing, including DNMT1-mediated DNA hypermethylation, EZH2-driven repressive histone modifications, and competing endogenous RNA (ceRNA) mediated post-transcriptional repression. miR-377 exerts convergent effects across multiple oncogenic pathways, including PI3K/AKT, Wnt/β-catenin, TGF-β, NF-κB, and MAPK signaling. Although predominantly tumor-suppressive, context-dependent oncogenic roles have also been reported, particularly in lung, hepatocellular, colorectal, and gastric cancer, underscoring the need for cancer- and isoform-specific interpretation. Circulating miR-377 shows potential as a non-invasive biomarker, though clinical validation remains limited. Preclinical strategies to restore miR-377 function include miRNA mimics, nanoparticle-based delivery, epigenetic reactivation, and CRISPR-based approaches; however, substantial translational barriers remain, and miR-377 restoration warrants further investigation in appropriately defined molecular and clinical settings.